Status:
UNKNOWN
A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
Lead Sponsor:
Wuhan University
Conditions:
Recurrent Ovarian Cancer
Eligibility:
FEMALE
18-70 years
Brief Summary
The purpose of this study is to evaluate the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.
Eligibility Criteria
Inclusion
- age between 18 and 70 years old
- singed the information consent form
- Expected survival time \>3 months
- Recurrence for at least 6 months after receiving initial platinum-based chemotherapy and without cytoreductive surgery indications.
Exclusion
- Recurrence within 6 months after receiving initial platinum-based chemotherapy
- without radiographic evidence for tumor recurrence
- receiving other chemotherapy, hormone therapy, immunotherapy, or radiation therapy
Key Trial Info
Start Date :
March 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2015
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01851746
Start Date
March 1 2013
End Date
February 1 2015
Last Update
May 10 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430071